Cargando…

Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center

BACKGROUND: A salutary effect of treatments for Gaucher disease (GD) has been a reduction in the incidence of avascular osteonecrosis (AVN). However, there are reports of AVN in patients receiving enzyme replacement therapy (ERT) , and it is not known whether it is related to individual treatments,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basiri, Mohsen, Ghaffari, Mohammad E, Ruan, Jiapeng, Murugesan, Vagishwari, Kleytman, Nathaniel, Belinsky, Glenn, Akhavan, Amir, Lischuk, Andrew, Guo, Lilu, Klinger, Katherine, Mistry, Pramod K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317498/ https://www.ncbi.nlm.nih.gov/pubmed/37249220 http://dx.doi.org/10.7554/eLife.87537

Ejemplares similares

Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease
por: Kleytman, Nathaniel, et al.
Publicado: (2021)

Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
por: Beshlawy, Amal El, et al.
Publicado: (2019)

Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy
por: Boddupalli, Chandra Sekhar, et al.
Publicado: (2022)

Simultaneous Bilateral Femoral Osteonecrosis in Gaucher Disease
por: Cohen, Daniel, et al.
Publicado: (2023)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

In-depth phenotyping for clinical stratification of Gaucher disease
por: D’Amore, Simona, et al.
Publicado: (2021)

The mutation spectrum in Indian patients with Gaucher disease
por: Bisariya, Vartika, et al.
Publicado: (2011)

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites in Gaucher Disease
por: Adhyaru, Kunal, et al.
Publicado: (2022)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Long-read single molecule real-time (SMRT) sequencing of GBA1 locus in Gaucher disease national cohort from Argentina reveals high frequency of complex allele underlying severe skeletal phenotypes: Collaborative study from the Argentine Group for Diagnosis and Treatment of Gaucher Disease
por: Drelichman, Guillermo I., et al.
Publicado: (2021)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Gaucher disease in Montenegro - genotype/phenotype correlations: Five cases report
por: Vujosevic, Snezana, et al.
Publicado: (2019)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease
por: Lebel, Ehud, et al.
Publicado: (2009)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis
por: Mirza, Muhammad, et al.
Publicado: (2018)

Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021)

Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries
por: Hůlková, Helena, et al.
Publicado: (2010)

The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease
por: Drelichman, Guillermo, et al.
Publicado: (2019)

Hepatocellular carcinoma in Gaucher disease: an international case series
por: Regenboog, Martine, et al.
Publicado: (2018)

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
por: Mistry, Pramod K, et al.
Publicado: (2009)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system
por: Narayanan, Praveena, et al.
Publicado: (2022)

Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease
por: Goobie, Gillian C., et al.
Publicado: (2019)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

Disease-drug pairs revealed by computational genomic connectivity mapping on GBA1 deficient, Gaucher disease mice
por: Yuen, Tony, et al.
Publicado: (2012)

Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial
por: Schiffmann, Raphael, et al.
Publicado: (2022)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Gaucher-Associated Parkinsonism
por: Li, Yaqiong, et al.
Publicado: (2015)

Gaucher disease: an update
por: Dumitrascu, Dan L.
Publicado: (2021)

Gaucher Disease for Hematologists
por: Özdemir, Gül Nihal, et al.
Publicado: (2022)

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
por: Mistry, Pramod, et al.
Publicado: (2020)

PB2551: GAUCHER DISEASE CURRICULUM: INCORPORATING GAUCHER DISEASE IN THE FIELD OF HEMATOLOGY
por: Symeonidis, Argiris, et al.
Publicado: (2023)

New patients to the Leeds spondyloarthritis clinic: is referral stratification working?
por: Thomas, Rebecca C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_di0q67s9jh16ao94h7fi9lnkdc